<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>PubMed Report</title>
  <style>
    body { font-family: Arial, sans-serif; margin: 24px; color: #222; }
    h1 { font-size: 20px; margin-bottom: 8px; }
    .query { margin-bottom: 16px; color: #444; }
    .article { border: 1px solid #ddd; border-radius: 8px; padding: 12px; margin-bottom: 16px; }
    .label { font-weight: bold; margin-top: 8px; }
    .text { margin: 4px 0 8px 0; }
  </style>
</head>
<body>
  <h1>Literature Search Report</h1>
  <div class="query">Search query: AML treatment</div>
  
                <div class="article">
                  <div class="label">English title</div>
                  <div class="text">Prognostic value of BTG1 for predicting decitabine sensitivity in de novo acute myeloid leukemia.</div>
                  <div class="label">English abstract</div>
                  <div class="text">Decitabine has demonstrated efficacy in the treatment of acute myeloid leukemia (AML), though therapeutic responses vary widely due to the disease&#x27;s inherent heterogeneity. To address this clinical challenge, we aimed to identify reliable biomarkers for predicting decitabine responsiveness in patients with AML. In our previous studies, integrated epigenetic and transcriptomic profiling identified BTG1 as a methylation-associated tumor suppressor gene correlated with decitabine sensitivity. We found that decitabine upregulates BTG1 expression through demethylation, and this upregulation enhances the sensitivity of AML cells to decitabine. BTG1 may exert its effect through the Wnt/β-catenin signaling pathway. Notably, BTG1 expression levels were significantly associated with treatment outcomes, including complete remission (CR) rates and measurable residual disease (MRD) negativity in patients receiving decitabine-containing regimens (either &quot;7 + 3&quot; or alternative combinations). Importantly, peripheral blood BTG1 mRNA expression levels reliably predicted therapeutic response to decitabine, establishing BTG1 as a robust biomarker of decitabine efficacy in AML management. Clinical trial registration: ChiCTR2000037928.</div>
                  <div class="label">Chinese title</div>
                  <div class="text">BTG1在预测初诊急性髓系白血病对地西他滨敏感性中的预后价值。</div>
                  <div class="label">Chinese abstract</div>
                  <div class="text">地西他滨在治疗急性髓系白血病（AML）中已显示出疗效，但由于该疾病固有的异质性，治疗反应差异显著。为应对这一临床挑战，我们致力于寻找可靠的生物标志物以预测AML患者对地西他滨的治疗反应。在前期研究中，通过整合表观遗传学与转录组学分析，我们发现BTG1是一个与地西他滨敏感性相关的甲基化相关抑癌基因。地西他滨可通过去甲基化作用上调BTG1表达，而这种上调能增强AML细胞对地西他滨的敏感性。BTG1可能通过Wnt/β-catenin信号通路发挥作用。值得注意的是，在接受含地西他滨方案（无论是“7+3”方案或其他联合方案）治疗的患者中，BTG1表达水平与完全缓解率、可测量残留病灶阴性率等治疗结局显著相关。尤为重要的是，外周血BTG1 mRNA表达水平可可靠预测患者对地西他滨的治疗反应，这确立了BTG1作为AML管理中地西他滨疗效的强效生物标志物。临床试验注册号：ChiCTR2000037928。</div>
                </div>
                
                <div class="article">
                  <div class="label">English title</div>
                  <div class="text">[The Effect of Serum Ferritin before Transplantation on Implantation in MDS and AML Patients after Unrelated Cord Blood Transplantation].</div>
                  <div class="label">English abstract</div>
                  <div class="text">To analyze the effect of high serum ferritin (SF) before transplantation on erythrocyte, granulocyte and platelet implantation in unrelated cord blood transplantation (UCBT) patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The medical records of 60 patients with MDS and AML who underwent UCBT in the First Affiliated Hospital of University of Science and Technology of China from January 2020 to December 2022 were retrospectively collected. According to the SF level before transplantation, they were divided into high SF group (SF≥1 000 μg/L, There was no correlation between the level of SF before transplantation and RBC infusion. After transplantation, the median implantation time of RBC in the high SF group was 28.5(14-149) d, which was longer than 21(10-83) d in the non-high SF group ( SF levels before cord blood transplantation in MDS and AML patients have an impact on post transplant erythroid implantation. Detecting and intervening of iron load in patients before transplant may be beneficial for improving implantation and prognosis. 移植前血清铁蛋白水平对MDS及AML患者脐血移植后植入的影响. 分析骨髓增生异常综合征（MDS）及急性髓细胞白血病（AML）患者移植前高血清铁蛋白（SF）对移植后粒系、红系和血小板植入的影响。. 回顾性收集2020年1月至2022年12月在中国科学技术大学附属第一医院进行非血缘脐血移植的60例MDS和AML患者的病历资料，根据移植前SF水平分为高SF组20例（SF≥1 000 μg/L）和非高SF组40例（SF&lt;1 000 μg/L）。分析比较两组患者移植前红细胞输注量、移植后红系、粒系和血小板植入时间、植入风险和预后。. 移植前SF水平与红细胞输注量无相关性。移植后，高SF组患者红系中位植入时间28.5（14-149）d，大于非高SF组的21（10-83）d( MDS及AML患者脐血移植前SF水平对移植后红系植入存在影响，对移植前患者铁负荷进行检测及干预可能有利于改善植入和预后。.</div>
                  <div class="label">Chinese title</div>
                  <div class="text">[移植前血清铁蛋白水平对MDS及AML患者非亲缘脐带血移植后植入效果的影响]。</div>
                  <div class="label">Chinese abstract</div>
                  <div class="text">分析骨髓增生异常综合征（MDS）及急性髓细胞白血病（AML）患者移植前高血清铁蛋白（SF）水平对非血缘脐血移植（UCBT）后红系、粒系及血小板植入的影响。回顾性收集2020年1月至2022年12月在中国科学技术大学附属第一医院接受UCBT的60例MDS和AML患者的病历资料。根据移植前SF水平，将患者分为高SF组（SF≥1 000 μg/L，20例）和非高SF组（SF&lt;1 000 μg/L，40例）。分析比较两组患者移植前红细胞输注量、移植后红系、粒系和血小板植入时间、植入成功率及预后情况。

结果显示，移植前SF水平与红细胞输注量无相关性。移植后，高SF组患者红系中位植入时间为28.5（14-149）天，长于非高SF组的21（10-83）天。研究表明，MDS及AML患者脐血移植前SF水平对移植后红系植入存在影响，对移植前患者铁负荷进行检测及干预可能有利于改善植入效果和预后。</div>
                </div>
                
</body>
</html>
